UT-MD Anderson Cancer Center: Combining Targeted Therapy and Immunotherapy Improves Overall Survival in Patients With Anaplastic Thyroid Cancer
October 25, 2024
October 25, 2024
HOUSTON, Texas, Oct. 25 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Approach achieved longest median overall survival published to date for systematic therapy in anaplastic thyroid carcinoma
* * *
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival . . .
* * *
Approach achieved longest median overall survival published to date for systematic therapy in anaplastic thyroid carcinoma
* * *
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival . . .